General description
AR-A014418 may have chronic pain-relieving properties. In mice having neuropathic pain, this molecule has been shown to have antihyperalgesic effects. AR-A014418 may modulate proinflammatory cytokines and the catecholaminergic and serotonergic pathways. It has also been studied that AR-A014418 inhibits growth of pancreatic cancer cells.
Application
AR-A014418 has been used as an inhibitor of glycogen synthase kinase 3 (GSK3).
Biochem/physiol Actions
AR-A014418 is a glycogen synthase kinase 3 (GSK3) inhibitor.
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer′s disease. GSK3 inhibitor, AR-A014418, inhibits GSK3 (IC50 = 104 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases, demonstrating high specificity for GSK3.
Features and Benefits
This compound is featured on the PKB/Akt page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | solid |
| color | off-white to tan |
| solubility | DMSO: ≥20 mg/mL, clear, light yellow,H2O: insoluble |
| originator | AstraZeneca |
| storage temp. | 2-8°C |
| SMILES string | COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1 |
| InChI | 1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17) |
| InChI key | YAEMHJKFIIIULI-UHFFFAOYSA-N |
